Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studies.

Xingsheng HuShucai ZhangZhiyong MaJifeng FengLin WuDongqing LvJianying ZhouXiaodong ZhangLi LiuQitao YuWangjun LiaoYiping ZhangXiang WangYing ChengHongrui NiuZiping WangDong WangCheng HuangChunling LiuHui ZhaoJian FengJingzhang LiKejing YingNong YangShukui QinJie HuFei LiuYong JiangNan GeYuan-Kai Shi

Published in: BMC medicine (2023)

Both studies were registered on ClinicalTrial.gov. The phase 2a study was registered with NCT03127449 on April 25, 2017; The phase 2b study was registered with NCT03452592 on March 2, 2018.

Keyphrases

small cell lung cancer
epidermal growth factor receptor
case control
tyrosine kinase
cerebrospinal fluid